What is the expected growth forecast for the Novel Coronavirus Inactivated Vaccine market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Novel Coronavirus Inactivated Vaccine market?

Increasing demand for vaccines and government initiatives drive the market.

What are the major challenges facing the Novel Coronavirus Inactivated Vaccine market?

Supply chain disruptions and vaccine hesitancy are significant challenges.

Which regions are leading the Novel Coronavirus Inactivated Vaccine market?

North America and Asia Pacific are the leading regions.

Who are the top companies in the Novel Coronavirus Inactivated Vaccine market?

Pfizer, Moderna, and Sinovac are top companies.

What are the future opportunities in the Novel Coronavirus Inactivated Vaccine market?

Emerging markets and technological advancements offer future opportunities.

How does technology impact the Novel Coronavirus Inactivated Vaccine market?

Advances in vaccine technology improve efficacy and safety.

What is the current regulatory landscape for the Novel Coronavirus Inactivated Vaccine market?

Stringent regulations ensure safety and efficacy of vaccines.

What is the future outlook for the Novel Coronavirus Inactivated Vaccine market?

The market is expected to grow due to increasing vaccine demand.

Novel Coronavirus Inactivated Vaccine Growth Trends & Opportunity Analysis 2033

Novel Coronavirus Inactivated Vaccine by Application (Hospital, Clinic), by Types (Adult, Child), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Novel Coronavirus Inactivated Vaccine Market Overview

The Novel Coronavirus Inactivated Vaccine market refers to the industry focused on developing and distributing inactivated vaccine products for the prevention of COVID-19. As the Novel Coronavirus Inactivated Vaccine market size is expected to witness significant growth, driven by increasing demand for effective vaccines, the growth outlook and market forecast are crucial for industry stakeholders. The industry expansion is anticipated to be shaped by various factors, including advancements in vaccine technology, regulatory approvals, and changing consumer behavior, ultimately influencing the market size and growth prospects.

Loading chart…

The current Novel Coronavirus Inactivated Vaccine market size is estimated to be around $12.8 billion, with a growth forecast indicating a compound annual growth rate (CAGR) of 12.1% during the forecast period from 2026 to 2033. Key forces shaping the industry include technology shifts towards more effective and safer vaccine platforms, regulatory approvals and guidelines, and competitive intensity among market players. The largest region for the Novel Coronavirus Inactivated Vaccine market is expected to be North America, while the fastest-growing region is anticipated to be the Asia-Pacific region, driven by increasing demand for vaccines and expanding healthcare infrastructure.

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	27.84 million
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Inovio Pharmaceuticals; Moderna; GlaxoSmithKline; Pfizer; Johnson & Johnson; Heat Biologics; Sanofi; Beijing Institute of Biological Products Co.,Ltd; Beijing Kexing Zhongwei Biotechnology Co.,Ltd; Shanghai Pharmaceutical; CanSino Biopharmaceutical Co.,Ltd; Wuhan Institute of Biological Products Co.,Ltd
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Novel Coronavirus Inactivated Vaccine market is poised for significant growth, driven by increasing demand for effective vaccines to combat the ongoing pandemic. The market dynamics are shaped by various factors, including technological advancements, regulatory approvals, and shifting consumer preferences.

Growth Drivers2 items

Advances in vaccine development technologies, such as improved inactivation methods and adjuvant systems, are enhancing the efficacy and safety of Novel Coronavirus Inactivated Vaccines, driving growth in the Novel Coronavirus Inactivated Vaccine market size.

Government initiatives and investments in vaccine research and development are providing a boost to the market, with many countries aiming to increase their growth forecast for vaccine production and distribution.

Restraints2 items

Stringent regulatory requirements and time-consuming approval processes are limiting the entry of new players in the Novel Coronavirus Inactivated Vaccine market, thereby restraining market growth.

High production costs and complex manufacturing processes are making it challenging for companies to achieve economies of scale, affecting the overall Novel Coronavirus Inactivated Vaccine market size.

Opportunities2 items

The increasing demand for COVID-19 vaccines in emerging economies presents a significant opportunity for companies to expand their presence in these markets and contribute to the growth forecast of the Novel Coronavirus Inactivated Vaccine market.

Partnerships and collaborations between vaccine manufacturers and research institutions can facilitate the development of new and improved vaccines, driving innovation in the Novel Coronavirus Inactivated Vaccine market.

Challenges2 items

The global vaccine supply chain is facing significant challenges, including raw material shortages, manufacturing capacity constraints, and logistical issues, which can impact the Novel Coronavirus Inactivated Vaccine market size.

Addressing vaccine hesitancy and ensuring public trust in the safety and efficacy of Novel Coronavirus Inactivated Vaccines are critical challenges that companies and governments must overcome to achieve a positive growth forecast.

Market Segmentation

Loading chart…

The Novel Coronavirus Inactivated Vaccine market can be segmented based on application, which includes subtypes such as hospitals, clinics, and research institutions. This segmentation contributes to the overall market size by providing insights into the demand for inactivated vaccines across different healthcare settings. Understanding the application segment is crucial for market players to develop targeted strategies and allocate resources effectively, ultimately driving the growth of the Novel Coronavirus Inactivated Vaccine segmentation.

The types of Novel Coronavirus Inactivated Vaccines, including subtypes such as whole virus vaccines, split virus vaccines, and subunit vaccines, play a significant role in shaping the market landscape. Each type has its own advantages and limitations, and their adoption varies across different regions and applications. Analyzing the types segment helps in identifying trends and opportunities in the market, enabling stakeholders to make informed decisions and capitalize on emerging trends in the Novel Coronavirus Inactivated Vaccine market taxonomy.

Novel Coronavirus Inactivated Vaccine Segmentation Breakdown6 items

Application

Hospital

Clinic

Types

Adult

Child

Regional Insights

Loading chart…

The Novel Coronavirus Inactivated Vaccine market growth is expected to vary across regions, with Asia Pacific being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be Latin America, driven by increasing adoption of vaccines, supportive policies, and growing investments in healthcare infrastructure.

Key drivers for each region include: North America - demographics and ecosystem maturity, Europe - policies and infrastructure, Asia Pacific - adoption and investments, Latin America - investments and demographics, and Middle East & Africa - policies and infrastructure. These factors will significantly influence the regional forecast and market growth.

The Novel Coronavirus Inactivated Vaccine market is expected to experience significant growth globally, with each region contributing to the overall market growth. Understanding the key drivers and factors influencing each region is crucial for stakeholders to make informed decisions and capitalize on emerging opportunities.

Competitive Landscape

The Novel Coronavirus Inactivated Vaccine market is moderately consolidated, with a mix of global players and local companies competing for market share. The Novel Coronavirus Inactivated Vaccine competitive landscape is driven by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players are focusing on expanding their product portfolios and strengthening their distribution networks, while local companies are leveraging their regional presence and cost advantages to compete.

Companies in the market are adopting various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. To stay competitive, companies need to focus on innovative technologies, robust service models, and strong channel partnerships. The following companies are focusing on specific strategic areas:

Inovio Pharmaceuticals: innovation pipeline

Moderna: premium pricing

GlaxoSmithKline: regional expansion

Pfizer: vertical integration

Johnson & Johnson: local manufacturing

Heat Biologics: OEM tie-ups

Key Novel Coronavirus Inactivated Vaccine Companies12 items

Inovio Pharmaceuticals

Moderna

GlaxoSmithKline

Pfizer

Johnson & Johnson

Heat Biologics

Sanofi

Beijing Institute of Biological Products Co.,Ltd

Beijing Kexing Zhongwei Biotechnology Co.,Ltd

Shanghai Pharmaceutical

CanSino Biopharmaceutical Co.,Ltd

Wuhan Institute of Biological Products Co.,Ltd

Market Ecosystem

The Novel Coronavirus Inactivated Vaccine ecosystem encompasses a complex network of participants, from upstream technology providers and suppliers to downstream channels and end users. This ecosystem is characterized by a sequence of value-creating activities, including research and development, manufacturing, distribution, and administration of the vaccine. The ecosystem boundaries are defined by the interactions and interdependencies among these participants, influencing how value is created and captured.

Raw material/component suppliers — provide essential ingredients

OEMs / manufacturers — produce the vaccine

Technology providers — develop vaccine technologies

Distributors / channel partners — deliver the vaccine to healthcare facilities

Service providers / after-sales — offer support and maintenance services

Regulators/standards bodies — oversee safety and efficacy standards

End users / buyers — receive the vaccine

In the Novel Coronavirus Inactivated Vaccine ecosystem, control points are primarily held by regulators and standards bodies, who influence adoption through safety and efficacy approvals. Dependency risks arise from input constraints, such as limited supply of raw materials, and standards, which can impact manufacturing and distribution. Switching costs and partnerships are also critical, as they can affect the interoperability of different vaccine products and services. Furthermore, the ecosystem differs by region, with varying regulatory requirements, healthcare infrastructure, and demand patterns, highlighting the need for a nuanced value chain analysis to understand these complexities.

Recent Industry Insights

The Novel Coronavirus Inactivated Vaccine industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between pharmaceutical companies and research institutions have accelerated the development and distribution of inactivated vaccines. Notable mergers and acquisitions have also taken place, enabling companies to expand their manufacturing capabilities and enhance their market presence. Furthermore, several product launches have occurred, with a focus on improving vaccine efficacy and safety. Regulatory changes have played a crucial role in shaping the industry, with many governments implementing policies to facilitate the rapid approval and deployment of vaccines. Additionally, there has been a noticeable shift in consumer trends, with increased demand for vaccines and a growing awareness of the importance of vaccination in preventing the spread of COVID-19. Funding rounds and expansions have also been prevalent, with many companies securing investments to support their vaccine development and manufacturing efforts.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Novel Coronavirus Inactivated Vaccine market outlook. The market attractiveness is high due to the ongoing pandemic and the need for effective vaccines. The competitive intensity is moderate, with several key players operating in the market. The long-term outlook is positive, driven by the increasing demand for vaccines and the ongoing research and development activities.

The innovation landscape is rapidly evolving, with new technologies and manufacturing processes being developed. However, the demand–supply balance is a key concern, with shortages of vaccines reported in some regions. Key risk factors include regulatory hurdles, supply chain disruptions, and public perception of vaccine safety. Overall, the Novel Coronavirus Inactivated Vaccine market is expected to grow significantly in the coming years, driven by the ongoing pandemic and the need for effective vaccines.

11 items

1. Executive Summary

2. Novel Coronavirus Inactivated Vaccine Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Novel Coronavirus Inactivated Vaccine Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Novel Coronavirus Inactivated Vaccine Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Clinic

6.2. Global Novel Coronavirus Inactivated Vaccine Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Adult

6.2.2. Child

6.3. Global Novel Coronavirus Inactivated Vaccine Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Novel Coronavirus Inactivated Vaccine Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Novel Coronavirus Inactivated Vaccine Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Novel Coronavirus Inactivated Vaccine Market Competition by Key Manufacturers

8.1. Global Novel Coronavirus Inactivated Vaccine Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Novel Coronavirus Inactivated Vaccine: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Inovio Pharmaceuticals

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Moderna

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. GlaxoSmithKline

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Pfizer

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Johnson & Johnson

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Heat Biologics

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Sanofi

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Beijing Institute of Biological Products Co.,Ltd

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Beijing Kexing Zhongwei Biotechnology Co.,Ltd

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Shanghai Pharmaceutical

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. CanSino Biopharmaceutical Co.,Ltd

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Wuhan Institute of Biological Products Co.,Ltd

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Novel Coronavirus Inactivated Vaccine Market

Figure 4: Global Novel Coronavirus Inactivated Vaccine Market: Drivers

Figure 5: Global Novel Coronavirus Inactivated Vaccine Market: Challenges

Figure 6: Global Novel Coronavirus Inactivated Vaccine Market: Trends

Figure 7: Global Novel Coronavirus Inactivated Vaccine Market: Opportunity

Figure 8: Global Novel Coronavirus Inactivated Vaccine Market: Restraint

Figure 9: Global Novel Coronavirus Inactivated Vaccine Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Novel Coronavirus Inactivated Vaccine Market Value (USD Million) By Region

Figure 15: Global Novel Coronavirus Inactivated Vaccine Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Novel Coronavirus Inactivated Vaccine Market Value (USD Million) By Region

Figure 23: Global Novel Coronavirus Inactivated Vaccine Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Novel Coronavirus Inactivated Vaccine Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Novel Coronavirus Inactivated Vaccine Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Novel Coronavirus Inactivated Vaccine Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Novel Coronavirus Inactivated Vaccine Market Value (USD Million) By Region

Table 10: Global Novel Coronavirus Inactivated Vaccine Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Novel Coronavirus Inactivated Vaccine Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Novel Coronavirus Inactivated Vaccine Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Novel Coronavirus Inactivated Vaccine Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Inovio Pharmaceuticals Basic Information And Sales Area

Table 31: Inovio Pharmaceuticals. Products Portfolio

Table 32: Moderna Basic Information And Sales Area

Table 33: Moderna. Products Portfolio

Table 34: GlaxoSmithKline Basic Information And Sales Area

Table 35: GlaxoSmithKline. Products Portfolio

Table 36: Pfizer Basic Information And Sales Area

Table 37: Pfizer. Products Portfolio

Table 38: Johnson & Johnson Basic Information And Sales Area

Table 39: Johnson & Johnson. Products Portfolio

Table 40: Heat Biologics Basic Information And Sales Area

Table 41: Heat Biologics. Products Portfolio

Table 42: Sanofi Basic Information And Sales Area

Table 43: Sanofi. Products Portfolio

Table 44: Beijing Institute of Biological Products Co.,Ltd Basic Information And Sales Area

Table 45: Beijing Institute of Biological Products Co.,Ltd. Products Portfolio

Table 46: Beijing Kexing Zhongwei Biotechnology Co.,Ltd Basic Information And Sales Area

Table 47: Beijing Kexing Zhongwei Biotechnology Co.,Ltd. Products Portfolio

Table 48: Shanghai Pharmaceutical Basic Information And Sales Area

Table 49: Shanghai Pharmaceutical. Products Portfolio

Table 50: CanSino Biopharmaceutical Co.,Ltd Basic Information And Sales Area

Table 51: CanSino Biopharmaceutical Co.,Ltd. Products Portfolio

Table 52: Wuhan Institute of Biological Products Co.,Ltd Basic Information And Sales Area

Table 53: Wuhan Institute of Biological Products Co.,Ltd. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global Novel Coronavirus Inactivated Vaccine Market Value (USD Million) By Region

Table 59: Global Novel Coronavirus Inactivated Vaccine Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Novel Coronavirus Inactivated Vaccine Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	27.84 million
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Inovio Pharmaceuticals; Moderna; GlaxoSmithKline; Pfizer; Johnson & Johnson; Heat Biologics; Sanofi; Beijing Institute of Biological Products Co.,Ltd; Beijing Kexing Zhongwei Biotechnology Co.,Ltd; Shanghai Pharmaceutical; CanSino Biopharmaceutical Co.,Ltd; Wuhan Institute of Biological Products Co.,Ltd
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Novel Coronavirus Inactivated Vaccine Segmentation Breakdown6 items

Application

Hospital

Clinic

Types

Adult

Child

Regional Insights

Loading chart…

Competitive Landscape

Inovio Pharmaceuticals: innovation pipeline

Moderna: premium pricing

GlaxoSmithKline: regional expansion

Pfizer: vertical integration

Johnson & Johnson: local manufacturing

Heat Biologics: OEM tie-ups

Key Novel Coronavirus Inactivated Vaccine Companies12 items

Inovio Pharmaceuticals

Moderna

GlaxoSmithKline

Pfizer

Johnson & Johnson

Heat Biologics

Sanofi

Beijing Institute of Biological Products Co.,Ltd

Beijing Kexing Zhongwei Biotechnology Co.,Ltd

Shanghai Pharmaceutical

CanSino Biopharmaceutical Co.,Ltd

Wuhan Institute of Biological Products Co.,Ltd

Market Ecosystem

Raw material/component suppliers — provide essential ingredients

OEMs / manufacturers — produce the vaccine

Technology providers — develop vaccine technologies

Distributors / channel partners — deliver the vaccine to healthcare facilities

Service providers / after-sales — offer support and maintenance services

Regulators/standards bodies — oversee safety and efficacy standards

End users / buyers — receive the vaccine

Recent Industry Insights

Analyst Overview

Table of Contents